Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

GCA Therapeutics to Commercialize Achillion’s HBV Treatment in China

publication date: Feb 2, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Achillion Pharmaceuticals out-licensed the China rights for elvucitabine, to GCA Therapeutics, Ltd. (GCAT) of Jersey City, New Jersey. Elvucitabine is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of both hepatitis B virus (HBV) and human immunodeficiency virus (HIV). GCAT has a China JV with Tianjing Institute of Pharmaceutical Research, which will be responsible for developing and commercializing the drug in China, Hong Kong and Taiwan. More details...

Stock Symbol: (NSDQ: ACHN)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners